Navigation Links
Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer
Date:5/15/2008

europathy," noted Vahdat. "None of the reported cases of neuropathy were disabling, suggesting that eribulin mesylate, if approved, may be a useful addition to the treatment armamentarium for advanced breast cancer."

About Eribulin Mesylate

Eribulin mesylate is being developed by Eisai as a potential new chemotherapeutic agent. It suppresses the growth of microtubules, which are involved in various cellular processes in the body, such as cell division. Eribulin mesylate is a synthetic analog of halichondrin B, a naturally occurring compound which was first isolated from a marine sponge Halichondria okadai in 1992.

About Eisai Corporation of North America

Eisai Corporation of North America is a wholly-owned subsidiary of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: neurology, gastrointestinal disorders and oncology/critical care.

Eisai Corporation of North America supports the activities of its operating companies in North America, which include: Eisai Research Institute of Boston, Inc., a discovery operation with strong organic chemistry capabilities; Morphotek, Inc., a biopharmaceutical company specializing in the development of therapeutic monoclonal antibodies; Eisai Medical Research Inc., a clinical development group; Eisai Inc., a commercial operation with manufacturing and marketing/sales functions; MGI PHARMA, INC., an R&D and commercial operation with manufacturing and marketing/sales functions; and Eisai Machinery U.S.A., which markets and maintains pharmaceutical manufacturing machinery.

(*) Censored observation.


'/>"/>
SOURCE Eisai Corporation of North America
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists
2. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
3. Results of VYVANSE(TM) (lisdexamfetamine dimesylate) Pivotal Trial in Adult ADHD Presented at Major Scientific Meeting
4. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
5. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
6. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
7. Milnacipran Demonstrated Significant Improvement in Pain and the Core Symptoms of Fibromyalgia Syndrome, Data Show
8. Data Presented at the American Heart Association Scientific Sessions 2007 Demonstrated Increased HDL with ACTOS(R) (pioglitazone HCl) Slowed the Progression of Carotid Intima-Media Thickness in Patients with Type 2 Diabetes
9. UPDATE: Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
10. Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
11. Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2008)...velopment Initiative bring MJFF,s,current active i...y 20,2009, NEW YORK, July 22 /PRNewswire-USNewsw...f transformative treatments and a cure for Parkins...rkinson,s Research has awarded,$2.7 million in tot...rds,were granted under MJFF,s Therapeutics Develop...
(Date:7/22/2008)... Apidra(R) Resulted in Significant, Reductions in ... Algorithm Used, ...s from the "Adjust to,Target in Type 2 Diabetes: C...unting for Adjustment of Mealtime Insulin Glulisin...Association,s (ADA) medical journal,Diabetes Care...
(Date:7/22/2008)...a University Medical Center Based on Ros...The Test Differentiates Squamous From Non-Squamous...Squamous-Cell Carcinoma of the Lung With Se...ent,This is the First CLIA Approved Test Which Lev...rs for Accurate Diagnosis of Lung Cancer, REHOVOT...
(Date:7/22/2008)...ew Approach of LASH (Laser Assisted Scar Heali...y, MARSEILLES, France, July 22 /- Ek...omedicine company, which develops first-in-class,l...duction, announced today,the publication of a scie...reporting the results of a pilot study on cutaneou...
Breaking Medicine Technology:Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 2Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 3Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 2Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 3Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 4First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 2First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 3First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 4First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 5Ekkyo Describes the First Benefits of Controlled Hyperthermia in Humans in "Lasers in Surgery and Medicine" 2Ekkyo Describes the First Benefits of Controlled Hyperthermia in Humans in "Lasers in Surgery and Medicine" 3CEL SCI Corporation Releases Letter to Shareholders 10228 1CEL SCI Corporation Releases Letter to Shareholders 10228 2CityVoter and ExerciseTV Partner to Launch ExerciseTV Top Trainer a Nationwide Search for Americas Top Fitness Trainers 10225 1CityVoter and ExerciseTV Partner to Launch ExerciseTV Top Trainer a Nationwide Search for Americas Top Fitness Trainers 10225 2CityVoter and ExerciseTV Partner to Launch ExerciseTV Top Trainer a Nationwide Search for Americas Top Fitness Trainers 10225 3CityVoter and ExerciseTV Partner to Launch ExerciseTV Top Trainer a Nationwide Search for Americas Top Fitness Trainers 10225 4Clontech Laboratories Inc Releases the ProteoTuner 28TM 29 Systems 2762 1Clontech Laboratories Inc Releases the ProteoTuner 28TM 29 Systems 2762 2Arbor Surgical Technologies Announces Series C Financing and Licensing Agreement with Medtronic 2759 1Arbor Surgical Technologies Announces Series C Financing and Licensing Agreement with Medtronic 2759 2
...GLE PARK, N.C. & SHERBROOKE, Quebec--(BUSINESS...biopharmaceutical,company developing small molecul...metabolic diseases, today announced positive,resul...lerating,gastric emptying in diabetic patients wit...tudy were presented at the American,Diabetes Assoc...
...technology Company updates progress and upcoming,m...26, 2007 /PRNewswire-FirstCall/ - SemBioSys,Geneti...tfolio of,therapeutic proteins for metabolic and c...eclinical data supporting the,development of plant...esented its findings at the 67th Scientific Sessio...
Other Medicine Technology:Tranzyme Pharma Presents Initial Phase IIa Data for its Novel,Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis 2Tranzyme Pharma Presents Initial Phase IIa Data for its Novel,Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis 3SemBioSys Presents Positive Insulin Data at the American Diabetes,Association Conference 2SemBioSys Presents Positive Insulin Data at the American Diabetes,Association Conference 3SemBioSys Presents Positive Insulin Data at the American Diabetes,Association Conference 4
(Date:7/25/2008)... HOUSTON, July 25 /PRNewswire/ -- The Elekta Famil...cancer treatment solutions at the 2008,American As...meeting,demonstrating how the joint forces of Ele...iation therapy planning and delivery solutions tha...ter experience for,patients, as well as enhance cl...
(Date:7/25/2008)...urday can be toughest for those trying to drop pou...althDay News) -- Anyone who has avoided Monday mor...nds are not a dieter,s friend. , Now, researche...s about weekends being their undoing: Most people ...ng to lose weight. , "Weekend indulgences can w...
(Date:7/25/2008)... The Drug Information Associ...FDA) will host the Critical Path Initiative (CPI) ...r 15 -16; Bethesda, MD) and the Critical Path Tran.... , Horsham, PA (PRWEB) J... Information Association (DIA)] and the Food and D...
(Date:7/24/2008)... Hoag to lease hospital faci... Newport Beach, CA (Vocus) July 24, 2008 -- Hoa...reement with HCP, Inc. (NYSE: HCP), a Real Estate ...to lease its 175-bed hospital facility on Sand Can..., , , ,The facility is currently operated by Tene...
Breaking Medicine News(10 mins):Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 2Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 3Health News:Weekends Tough on the Diet 2Health News:Weekends Tough on the Diet 3Health News:DIA And FDA To Host Two Important Critical Path Workshops 2Health News:DIA And FDA To Host Two Important Critical Path Workshops 3Health News:Hoag Hospital Announces Agreement to Open Irvine Campus 2
...esperate to stun people with the way she looks, fo....3 kilograms in one month . The 26-year-old is on ...by her celeb trainer Harley Pasternak, and she eve...e nutritional meals delivered to her doorstep. Sim...
...ted that circumcision 'significantly' cuts HIV ris...ess important as a deterrent to the global AIDS pa...bott who conducted statistical empirical research ...the world conducted the study. He found that the n...
...stitute have found in animal models just how great...celerating breast cancer . Until this study, the s...east cancer had not been clearly established, and ...dings could lead to a better understanding of the ...
...red an inquiry into the alleged incident of a 15-y...on, an official said Thursday. In April, Dileepa...ction operation under his parents' supervision at ...spital in Manapparai, about 450 km from the state ...
Other Medicine News:Health News:Male Circumcision Overstated as Deterrent to Global AIDS Pandemic 2Health News:Researchers Have Found the Role of Protein in Accelerating Breast Cancer Progression 2Health News:Researchers Have Found the Role of Protein in Accelerating Breast Cancer Progression 3
...iagnostic collection software. Sandman Elite versi...collection software offers customizable digital fi...post recording. The scoring displays a list of sco...ing current number of events, frequency and averag...
...ur SleepWorks software and Hyppo headbox. XLTEK's ...ostic sleep-testing needs. It's compliant, accurat...ked up by 24/7 support provided by a team of knowl...t, you can expand your capabilities to include cli...
... in the Beehive product line, combines decades of ...ogy of the 21st century. Beehive Millennium is a p..., providing complete data acquisition, recording a...ilepsy monitoring applications. Beehive Millennium...
...ged unit capable of handling a wide range of stimu... research laboratories. The built-in isolation cir...s artifacts. The twin pulse circuit makes this sti...n Signal Marker For those investigators requiring ...
Medicine Products: